628733-99-3Relevant academic research and scientific papers
HETEROCYCLIC COMPOUNDS AS JANUS KINASE INHIBITORS
-
Page/Page column 134; 135; 136, (2013/03/28)
The invention provides compounds of formula I: (I) or a salt thereof as described herein. The invention also provides pharmaceutical compositions comprising a compound of formula I, processes for preparing com-pounds of formula I, intermediates useful for preparing com-pounds of formula I and therapeutic methods for suppressing an immune response or treating cancer, including a hematologic malignancy, using compounds of formula I
SULFONAMIDE, SULFAMATE, AND SULFAMOTHIOATE DERIVATIVES
-
Page/Page column 24, (2012/04/05)
The disclosure provides biologically active compounds of formula (I): and pharmaceutically acceptable salts thereof, compositions containing these compounds, and methods of using these compounds in a variety applications, such as treatment of diseases or disorders associated with E1 type activating enzymes, and with Nedd8 activating enzyme (NAE) in particular.
PYRROLO [1, 2-B] PYRIDAZINE DERIVATIVES AS JANUS KINASE INHIBITORS
-
Page/Page column 87, (2011/02/24)
The invention provides compounds of formula l: ( I ) or a salt thereof as described herein. The invention also provides pharmaceutical compositions comprising a compound of formula I, processes for preparing compounds of formula I, intermediates useful for preparing compounds of formula I and therapeutic methods for suppressing an immune response or treating cancer or a hematologic malignancy using compounds of formula I.
HETEROCYCLIC COMPOUNDS AS JANUS KINASE INHIBITORS
-
Page/Page column 88-89, (2011/12/14)
The invention provides compounds of formula I: or a salt thereof as described herein. The invention also provides pharmaceutical compositions comprising a compound of formula I, processes for preparing compounds of formula I, intermediates useful for preparing compounds of formula I and therapeutic methods for suppressing an immune response or treating cancer or a hematologic malignancy using compounds of formula I.
PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS
-
Page/Page column 400-401, (2010/08/05)
The present invention provides a compound of formula (I) or a salt form thereof, wherein Q1, Q2, Q3, and Q4 are as defined herein. The compound of formula (I) has ALK and/or JAK2 inhibitory activity, and may be used to treat proliferative disorders.
Pyrrolotriazinone compounds and their use to teat diseases
-
, (2008/06/13)
The present invention provides compounds of formula I and pharmaceutically acceptable salts thereof useful for inducing mitotic arrest thereby making them useful as anti-cancer agents and other diseases which can be treated by inducing mitotic arrest.
PYRROLOTRIAZINONE COMPOUNDS AND THEIR USE TO TREAT DISEASES
-
Page 44, (2010/02/04)
The present invention provides compounds of Formula (I), and pharmaceutically acceptable salts thereof useful for inducing mitotic arrest thereby making them useful as anti-cancer agents and other diseases which can be treated by inducing mitotic arrest.
